HC Wainwright maintains Buy on Evotec, lowers price target to $4

0 min read Updated on 15 Jul 2026, 04:29 PM

Reviewed by

Radhika SScanX News Team

AI Summary

HC Wainwright & Co. analyst Swayampakula Ramakanth maintained a Buy rating on Evotec (NASDAQ: EVO) but lowered the price target from $7 to $4.

*this image is generated using AI for illustrative purposes only.

HC Wainwright & Co. analyst Swayampakula Ramakanth has maintained a Buy rating on Evotec (NASDAQ: EVO) while adjusting the valuation outlook. The firm lowered the price target to $4 from the previous $7, reflecting a revised assessment of the stock's potential.

Rating and Price Target Details

The decision to retain the Buy recommendation suggests confidence in the company's long-term prospects despite the reduced price objective. The new target of $4 represents a significant decrease from the prior $7 level set by the analyst.

Metric	Value
Rating	Buy
Previous Price Target	$7
New Price Target	$4

What specific factors led to the 43% reduction in the price target despite the maintained Buy rating?

How might this revised valuation impact investor sentiment toward Evotec in the short term?

What upcoming milestones or catalysts could help restore confidence in Evotec's stock performance?

Read Next Article

Evotec cuts FY26 outlook as H1 revenue falls to €300.1 million

1 min read Updated on 14 Jul 2026, 02:44 AM

Reviewed by

Shriram SScanX News Team

Add as a preferred
source on Google

AI Summary

Evotec SE reduced its full-year 2026 guidance for Group revenues to €570-610 million and adjusted Group EBITDA to -€70 to -105 million, following preliminary H1 revenue of €300.1 million. The company reported liquidity of €465.6 million as of June 30, 2026, with full results due on August 13, 2026.

*this image is generated using AI for illustrative purposes only.

Evotec SE lowered its full-year 2026 guidance after reporting preliminary unaudited financial results for the first half of the year, citing weaker-than-expected performance. The company now anticipates full-year Group revenues of approximately €570 to 610 million, down from the previous guidance of €700 to 780 million. Adjusted Group EBITDA is now projected to be between -€70 and -€105 million, a sharp decline from the previously expected range of €0 to 40 million.

Based on preliminary figures, Evotec recorded Group revenues of approximately €300.1 million for the first half of 2026. Adjusted Group EBITDA for the same period stood at approximately -€42.7 million. As of June 30, 2026, the company reported liquidity of approximately €465.6 million.

The revised outlook reflects current operational performance and market conditions. Full financial results for the second quarter and first half of 2026 are scheduled to be published on August 13, 2026.